الفهرس 
Title : Retrospective study to assess impact of hcv infection on prognosis and management of multiple myeloma
AbstractOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
Objective: To assess impact of HCV infection on prognosis and management of Multiple Myeloma and to report the experience of Kasr Alaini clinical oncology department in managing multiple myeloma. Methods: from January 2009 to April 2019 a ten -year retrospective study of multiple myeloma patients in Kasr Alaini clinical oncology department (NEMROCK) was conducted. We accessed NEMROCK database to extract the file numbers of the patients diagnosed with multiple myeloma. Results: The median age was 51 years in HCV-ve group and 54 years in HCV+ve group with statistically significant difference (P- value < 0.001). We had 150 patients, 109 (72.7%) were HCV negative, 24(16%) patients were HCV positive and 17(11.3%) patients with unknown HCV status. The median overall survival for the HCV negative group of patients was 31.11 months and survival for the HCV positive group of patients was 37.66 months. After multivariate analysis age grouping, creatinine level and haemoglobin level correlated significantly with OS (P = 0.009, 0.008, 0.031 respectively). The median progression free survival (PFS) for all patients was 18.9 months, for HCV positive patients was 15.36 months and for HCV negative patients was 20.49 months. Multivariate analysis revealed that age below 60 and creatinine level less than 2 were statistically significant for better DFS in multivariate analysis (p = 0.030, 0.034 respectively) Conclusion: No difference in baseline characteristics between the two groups apart from ALT and platelet count related to HCV infection. Regarding the toxicity it was more in HCV positive patients but there was no statistically significant difference in overall survival and progression free survival between HCV positive and HCV negative patients, so HCV infection should not contraindicate MM therapy